BVXV
Income statement / Annual
Last year (2022), BiondVax Pharmaceuticals Ltd.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, BiondVax Pharmaceuticals Ltd.'s net income was -$531.00 K.
See BiondVax Pharmaceuticals Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$2.75 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.77 M
|
$10.34 M
|
$16.00 M
|
$68.65 M
|
$19.09 M
|
$18.78 M
|
$7.79 M
|
$7.91 M
|
$5.49 M
|
$5.45 M
|
| General & Administrative Expenses |
$0.00
|
$23.98 M
|
$16.14 M
|
$9.35 M
|
$5.09 M
|
$4.75 M
|
$4.06 M
|
$3.26 M
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
-$10.95 M
|
$0.00
|
$65.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.30 M
|
$23.98 M
|
$5.19 M
|
$9.35 M
|
$5.15 M
|
$4.75 M
|
$4.06 M
|
$3.26 M
|
$2.65 M
|
$2.19 M
|
| Other Expenses |
$0.00
|
$509.00 K
|
-$23.48 M
|
$352.00 K
|
$65.00 K
|
$130.00 K
|
$48.00 K
|
$133.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$11.06 M
|
$34.83 M
|
-$2.28 M
|
$78.35 M
|
$20.46 M
|
$23.66 M
|
$11.90 M
|
$6.72 M
|
$8.14 M
|
$7.64 M
|
| Cost And Expenses |
$11.06 M
|
$34.83 M
|
-$2.28 M
|
$78.35 M
|
$20.46 M
|
$23.66 M
|
$11.90 M
|
$11.30 M
|
$8.14 M
|
$7.64 M
|
| Interest Income |
$5.27 M
|
$3.00 K
|
$1.20 M
|
$4.00 K
|
$779.57 K
|
$18.00 K
|
$55.00 K
|
$11.00 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$10.83 M
|
$4.86 M
|
$14.92 M
|
$3.61 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$562.00 K
|
$2.39 M
|
$2.44 M
|
$1.49 M
|
$260.00 K
|
$440.00 K
|
$621.00 K
|
$628.00 K
|
$677.00 K
|
$709.00 K
|
| EBITDA |
-$10.50 M |
-$26.76 M |
$5.91 M |
-$92.78 M |
-$19.68 M |
-$12.30 M |
-$11.28 M |
-$10.68 M |
-$7.47 M |
-$6.93 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$5.27 M
|
-$5.15 M
|
-$2.43 M
|
-$30.84 M
|
$0.00
|
-$10.90 M
|
$2.72 M
|
$1.10 M
|
$378.00 K
|
-$395.00 K
|
| Income Before Tax |
-$5.80 M
|
-$39.98 M
|
-$1.39 M
|
-$109.19 M
|
-$23.29 M
|
-$34.55 M
|
-$9.18 M
|
-$10.20 M
|
-$7.76 M
|
-$8.04 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$5.27 M
|
$10.83 M
|
-$8.20 M
|
$14.92 M
|
$2.89 M
|
$0.00
|
-$55.00 K
|
-$11.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$531.00 K
|
-$50.81 M
|
$6.82 M
|
-$124.11 M
|
-$23.29 M
|
-$34.55 M
|
-$9.18 M
|
-$10.20 M
|
-$7.76 M
|
-$8.04 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.2 |
-36 |
6.15 |
-151.98 |
-35.64 |
-68.75 |
-27.19 |
-38.66 |
-23.76 |
-24.59 |
| EPS Diluted |
-0.2 |
-36 |
6.15 |
-151.98 |
-35.64 |
-68.75 |
-27.19 |
-38.66 |
-23.76 |
-24.59 |
| Weighted Average Shares Out |
$2.59 M
|
$1.41 M
|
$1.11 M
|
$816.63 K
|
$653.55 K
|
$502.58 K
|
$337.74 K
|
$263.81 K
|
$326.74 K
|
$326.74 K
|
| Weighted Average Shares Out Diluted |
$2.59 M
|
$1.41 M
|
$1.11 M
|
$816.63 K
|
$653.55 K
|
$502.58 K
|
$337.74 K
|
$263.81 K
|
$326.74 K
|
$326.74 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
